Document Classification

Section Type: RESULTS

Text: Aclidinium significantly increased sGaw compared with placebo at all assessments and doses (sGaw mean + / - SD AUC (l kPa (-1) h) for placebo 24. 4 + / - 4. 37, for 50 microg 29. 0 + / - 7. 08, for 300 microg 31. 2 + / - 6. 68 and for 600 microg 32. 7 + / - 7. 95) (P < 0. 009), except 50 microg at 1 and 24 h. Significant decreases in Raw were observed with aclidinium 300 and 600 microg compared with placebo at all assessments (Raw mean + / - SD AUC (kPa s (-1) l (-1) h) for placebo 7. 7 + / - 3. 46, for 300 microg 5. 8 + / - 2. 33, for 600 microg 6. 3 + / - 3. 11) (P < 0. 04) except 600 microg at 24 h. Differences between aclidinium 300 and 600 microg vs. placebo in PC35 doubling concentration were significant at all assessments (mean + / - SD AUC (mg ml (-1) h) for placebo 100. 0 + / - 30. 27, for 50 microg 117. 2 + / - 33. 33, for 300 microg 168. 9 + / - 28. 66 and for 600 microg 179. 1 + / - 15. 73 (P < 0. 0001).